News

CUTISS Announces First Reconstructive Surgery under Compassionate Use and First U.S. Patient Treated with denovoSkin™

Boston, MA and Switzerland, 10 October 2024 – CUTISS AG, a life sciences company at the forefront of tissue engineering therapy and regenerative medicine, announced the first ever grafting of denovoSkin™, its autologous, bio-engineered dermo-epidermal skin graft, in a compassionate reconstructive procedure, with the patient also being the first ever U.S....

read more

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will present on its lead-212 (212Pb)-labeled Radio-DARPin Therapeutic (RDT) targeting delta-like...

read more